

# CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein

Lichun Tang<sup>1,2</sup>  · Yanting Zeng<sup>3</sup> · Hongzi Du<sup>3</sup> · Mengmeng Gong<sup>1</sup> · Jin Peng<sup>1</sup> · Buxi Zhang<sup>1</sup> · Ming Lei<sup>3</sup> · Fang Zhao<sup>4</sup> · Weihua Wang<sup>5</sup> · Xiaowei Li<sup>6</sup> · Jianqiao Liu<sup>3</sup>

Received: 8 July 2016 / Accepted: 10 February 2017  
© Springer-Verlag Berlin Heidelberg 2017

**Abstract** Previous works using human tripronuclear zygotes suggested that the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system could be a tool in correcting disease-causing mutations. However, whether this system was applicable in normal human (dual pronuclear, 2PN) zygotes was unclear. Here we demonstrate that CRISPR/Cas9 is also effective as a gene-editing tool in human 2PN zygotes. By injection of Cas9 protein complexed with the appropriate sgRNAs and homology donors into one-cell human embryos, we demonstrated efficient homologous recombination-mediated correction of point mutations in *HBB* and *G6PD*. However, our results also reveal limitations of this correction procedure and highlight the need for further research.

Communicated by S. Hohmann.

L. Tang, Y. Zeng, H. Du and M. Gong contributed equally to the work.

**Electronic supplementary material** The online version of this article (doi:10.1007/s00438-017-1299-z) contains supplementary material, which is available to authorized users.

✉ Lichun Tang  
1212qq-@163.com

✉ Xiaowei Li  
lxw7402@126.com

✉ Jianqiao Liu  
ljq88gz@163.com

<sup>1</sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China

<sup>2</sup> National Center for Protein Sciences Beijing, Life Sciences Park, Beijing 102206, China

**Keywords** CRISPR/Cas9 · Homology-directed repair (HDR) · Cas9 protein · Gene modification · Human zygotes

## Introduction

There are many hundreds of disease-causing single-gene mutations and often there are no cures for these diseases. Correcting disease-causing genetic defects in human zygotes was previously unthinkable because the efficiency would be too low to be of any practical value. CRISPR/Cas9 offers, for the first time, a tangible potential to allow the correction of genetic defects (Cong et al. 2013; Mali et al. 2013; Niu et al. 2014). Separately from the debate of the merit and ethics of germline editing in humans, the feasibility of correcting genetic defects via CRISPR technology in human zygotes has not been really tested. Two recent reports used 3PN (3 or more pronuclei) human zygotes to test gene editing efficiency and the reported HDR efficiencies were only around 10% (Liang et al. 2015; Kang et al. 2016).

<sup>3</sup> Center for Reproductive Medicine, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou 510150, China

<sup>4</sup> National Center for International Research of Biological Targeting Diagnosis and Therapy, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Guangxi 530021, China

<sup>5</sup> Houston Fertility Institute, Houston, TX 77063, USA

<sup>6</sup> Department of Cardiology, Bai Hospital Affiliated Nanjing University of Chinese Medicine, Nanjing 210002, China

Gene editing has been demonstrated in many cells including cultured human cells and fertilized rodent and non-human zygotes and is easily achieved using a specific single guide RNA (sgRNA) to guide and target the Cas9 protein to the sequence position to be modified (Li et al. 2013; Shen et al. 2013; Niu et al. 2014). The Cas9/sgRNA complex creates a DNA double-strand break (DSB) at the targeted site, which triggers the endogenous DNA repair system, resulting in targeted genome modifications. DSB can be repaired in the cell by two major pathways, homology-directed repair (HDR) or non-homologous end joining (NHEJ) depending on the cell state and the presence of a repair template (Lieber 2010; Chapman et al. 2012). Precise genome editing is required to repair genetic defects and largely depends on the HDR repair pathway, which functions in the late S–G2 phase (Heyer et al. 2010). The efficiency of HDR is determined by the time of generation of the DSB site, the concentration of donor DNA, and the length of the homology arms of the donor DNA (Hasty et al. 1991; Lin et al. 2014a). The Cas9 protein can be provided from a Cas9 expression plasmid or Cas9 mRNA to bypass the transcription or translation steps to generate protein, and can generate DSB site quickly at designed sites. By controlling the time of injection, we can easily control the time of generation of DSB site (Lin et al. 2014a). Cas9 protein is degraded rapidly in cells, which may reduce off-target effects (Kim et al. 2014). A number of investigators have used Cas9 protein (instead of its mRNA) to edit genes in other models (Cho et al. 2013; Lee et al. 2014; Chen et al. 2016; Hashimoto et al. 2016). Here we show that Cas9-mediated gene editing is highly efficient in human 2PN zygotes. Homology-directed repair occurred in both the embryos carrying the *G6PD* G1376T mutation. Our work shows the feasibility of the correction of disease-causing genetic defects in human zygotes.

## Materials and methods

### Cas9/sgRNA production and injection

In vitro transcription and production of sgRNAs were performed as described (Zhou et al. 2014). Briefly, sgRNA oligos were annealed and ligated into the pUC57-sgRNA expression vector (Niu et al. 2014; Zhou et al. 2014), transcribed in vitro using the MEGAscript Kit (Ambion), and purified with the MEGAclear Kit (Ambion). The sgRNAs were concentrated by ethanol precipitation. Recombinant Cas9 protein was purchased from PNA Bio (Thousand Oaks, CA). Cas9 mRNA was purchased from ViewSolid Biotech (Beijing, China).

The Cas9 protein and sgRNAs were diluted into injection buffer (0.25 mM EDTA/10 mM TrisHCl, pH7.4) and

incubated for 10 min at 37 °C before injection. The final concentration of Cas9 was 50 ng/μl, and that of sgRNA was 30 ng/μl. The donor oligos were present at 100 ng/μl for the injection. The oligo sequences are listed in the supplemental material. Microinjection was performed under an inverted microscope equipped with micromanipulators and a microinjector (FemtoJet, Eppendorf).

### Source of embryos

Patients undergoing IVF treatment at the Center for Reproductive Medicine, at the Third Affiliated Hospital of Guangzhou Medical University, gave signed informed consent for the use of their 3PN embryos for research. They also gave signed informed consent for use of their immature oocytes and leftover sperm to produce normal (2PN) zygotes for research. The collection of oocytes and the culture of early embryos were performed routinely in the clinic using standard procedures. The zygotes were observed under an inverted microscopy 16–18 h after the insemination and the 3PN embryos were selected for experiments.

To obtain 2PN zygotes, the immature oocytes were transferred to maturation medium (Cooper Surgical/SAGE, Trumbull, CT) supplemented with 75 mIU/ml FSH and LH. After in vitro maturation, the oocytes were fertilized by intracytoplasmic sperm injection (ICSI). The fertilization was confirmed by formation of two pronuclei 16–18 h later.

### Molecular analyses

Genomic DNA from cultured embryos was amplified with the REPLI-g Single Cell Kit (QIAGEN) according to the manufacturer's instructions. Genomic regions of interest were further amplified from the WGA (whole genome amplified) DNA with KOD FX DNA polymerase (Toyobo) under the following PCR conditions: 95 °C for 5 min followed by 40 cycles of (98 °C for 10 s, 60 °C for 30 s, and 68 °C for 1 min), and then 68 °C for 5 min. The amplified fragments were gel-purified, cloned into the pGEMT-easy vector (Promega) for sequencing, or subjected to the T7E1 assay (Niu et al. 2014). PCR primers are listed in Table S1 (see supplemental material).

Whole genome sequencing (WGS) and WGS data analysis were performed by Beijing Genomics Institute (BGI). In brief, the amplified DNA was sequenced as paired-end 90-nucleotide reads to a target of 30X haploid coverage on an Illumina HiSeq2000 sequencer. The pair-end reads were aligned onto the hg19 (GRCh37v.71) human reference genome after removing reads containing sequencing adapters and low-quality reads with more than five ambiguous bases using BWA (v0.5.9) with default parameters. The variants identified were then further filtered through


dbSNP132 (<http://www.ncbi.nlm.nih.gov/SNP/>), 1000 Genomes (<http://www.1000genomes.org/>), or ESP6500 (<http://evs.gs.washington.edu/EVS/>) databases.

## Results

### Gene editing in human 3PN using Cas9 protein

We tested the efficiency of Cas9 protein-mediated gene editing in human fertilized oocytes. We collected the would-be-discarded one-cell embryos because of their triploid (3PN, 3 pronuclei) nature for experiments. The embryos were collected in our reproductive clinic in Guangzhou, China, and

the patients consented for the use of their 3PN embryos in research. In our routine practice, 16–18 h after insemination (when the pronucleus becomes prominent and visible), the embryos are observed under a microscope and the 3PN embryos are separated. We produced an sgRNA that targeted *RAG1* (Fig. 1a) in vitro and mixed it with the purified Cas9 protein and injected the mixture into the cytoplasm of the 3PN one-cell embryos. We found concentrations of 50 ng/μl Cas9 with 30 ng/μl sgRNA were effective and did not interfere with the development of the injected embryos (Fig. 1b). The embryos were cultured for 48 h in vitro after injection. By then, most of them, as expected, had reached the early morula stage (8–13 cells) (Fig. 1b). The embryos were harvested and their genomic DNA was extracted,



**Fig. 1** Gene editing in human 3PN zygotes using Cas9 protein. **a** Diagram of *RAG1* locus. The red-colored sequence is the sgRNA, and the green-colored sequence is the PAM motif. Sequencing results of three embryos are also shown. Numbers in the parentheses indicate the type of editing (“-19” means deletion of 19 bp and “+3” is the insertion of 3 bp) and its apparent frequency (“3/20” means 3 times in

20 clones sequenced). **b** Images of the embryos 3 days after the injections. Scale bar 100 μm. **c** A typical result of the T7E1 assay used to detect editing in targeted loci. **d** The number of independent edited alleles observed by sequencing. For each gene we randomly selected 6 T7E1 assay-positive embryos (E1–E6), cloned, and sequenced the PCR products. (Color figure online)

amplified with a whole genome amplification (WGA) kit, and subjected to molecular analyses. A pair of primers flanking the target site in *RAG1* was used to amplify the targeted region. The PCR-amplified products were denatured, re-annealed, and digested with T7 endonuclease I (T7E1), which cuts at mismatched sites (Fig. 1c). Of a total of 21 injected 3PN embryos, 12 (60%) showed cleavage products, indicating *RAG1* targeted editing. This *RAG1* targeting efficiency is comparable with the reported efficiency of 9/15 (60%) observed for Cas9 mRNA/sgRNA injection into cynomolgus monkey one-cell embryos (Niu et al. 2014). We also cloned the PCR products and sequenced 20 clones for 6 of the 12 samples that were positive in the T7E1 assay. Typical indels were observed (Fig. 1a). Some embryos contained up to 3 different indels, indicating independent editing of different alleles (Fig. 1d).


Having demonstrated efficient indel creation in *RAG1* (60%) by NHEJ editing, we next tested editing two additional loci, *G6PD* and *NEK1*, to assess the general applicability of this method. 2 sgRNAs targeting *G6PD* (1 bp overlap on different strands, Fig. 2a) and 1 targeting *NEK1* (Table S1) were tested. Again, up to three independent editing events were observed at the two loci (Fig. 1d). The *G6PD* sgRNA1 showed about 80% efficiency and *G6PD*

sgRNA2 and *NEK1* sgRNA were close to 70% (Table 1). This overall efficiency was comparable with the efficiencies reported previously in rodents of between 50 and 90% (Wang et al. 2013; Ma et al. 2014).

### Homologous recombination in human 3PN embryos

Encouraged by the high observed efficiencies of generating an indel mutation (NHEJ editing) at the selected loci using Cas9 protein, we next attempted to determine the HDR efficiency in human 3PN embryos using Cas9 protein. As shown previously, when Cas9 protein is introduced to human cells via electroporation, DSB generated by Cas9 can be achieved within 3 h (Kim et al. 2014). The 3PN embryos were collected about 16–18 h after insemination, at which time the S phase had commenced or even completed (Capmany et al. 1996) and, therefore, the embryos were in a cell cycle phase that was permissive for HDR. We chose two loci to determine Cas9-mediated HDR efficiency, *G6PD* and *HBB* ( $\beta$ -globin). It was reported previously that the use of a single-strand oligo donor (ssODN) as a source of homologous sequence for HDR required 20–50 bases of homology on each side of the DSB site (Chen et al. 2011). Therefore, for *G6PD*,

**Fig. 2** Homologous recombination at *G6PD*. **a** Diagram of the *G6PD* locus, *G6PD* sgRNA1 and *G6PD* sgRNA2 sequences (red), PAM motif (green), and the sequence of the single-strand donor oligo (ssODN1). The black arrows between nucleotides indicate the position of the Cas9 cut site and the extra bases introduced at the site. **b** Analyses of the *G6PD* locus targeted by *G6PD* sgRNA1 in ten embryos. M, DNA molecular weight marker, 1000, 750, 500, and 250 bp (top to bottom). \*T7E1 assay-positive samples, and \*\*HDR. **c** Sequencing results of embryos #3 and #8. (Color figure online)



**Table 1** CRISPR/Cas9-mediated gene editing in human embryo samples

Group	Injected zygotes	NHEJ editing (% embryos)	HDR editing (% embryos)
Cas9+ <i>RAG1</i> sgRNA	21	12 (60)	–
Cas9+ <i>NEK1</i> sgRNA	13	9 (69)	–
Cas9+ <i>G6PD</i> sgRNA1	15	12 (80)	–
Cas9+ <i>G6PD</i> sgRNA2	12	9 (75)	–
Cas9+ <i>G6PD</i> sgRNA1+ssODN1	10	9 (90)	2 (20)
Cas9 mRNA+ <i>G6PD</i> sgRNA1+ssODN1	20	16 (80)	0 (0)
Cas9+ <i>HBB</i> sgRNA1+ssODN2	10	7 (70)	1 (10)
Cas9+ <i>HBB</i> sgRNA2+ssODN3	4 <sup>a</sup>	2 (50)	1 (25)
Cas9+ <i>G6PD</i> sgRNA3+ssODN4	2 <sup>b</sup>	1 (50)	2 (100)

<sup>a,b</sup>The number of embryos carrying sgRNA target mutation allele

we designed a ssODN of 90 nt (ssODN1) in length containing two additional bases relative to the wildtype (to create a *HindIII* site for easy identification). This was injected into 3PN embryos with the Cas9 protein and *G6PD* sgRNA1 (Fig. 2a) at about 20 h post-insemination and the injected embryos were harvested for analyses after 2 days of culture when they had reached the early morula stage. Of the ten 3PN embryos injected, nine of them showed editing at the *G6PD* locus, and two of those contained the designed *HindIII* site, indicating a HDR efficiency of 20% (Fig. 2b). Sequencing of the region did not detect any additional sequence changes besides HDR (Fig. 2c). The two extra bases in the donor were within the region targeted by the *G6PD* sgRNA1, which likely prevented re-editing of the site after HDR. We also performed injection using Cas9 mRNA (100 ng/μl) instead of Cas9 protein and analyzed the HDR efficiency at the same locus. Of a total of 20 3PN embryos injected, 16 (80%) showed cleavage in the T7E1 assay, but none of them were sensitive to digestion with *HindIII*, indicating no HDR occurred. These data suggest that using Cas9 protein instead of mRNA promotes precise HDR genome modifications in our conditions.


For the second locus, *HBB*, we tested if HDR could occur at a site positioned some distance from the DSB generated by Cas9. We designed an sgRNA (*HBB* sgRNA1) and a 200 nt oligo donor (ssODN2) so that the intended genetic alteration (a *HindIII* site) was positioned 39 bases 3' of the predicted Cas9 cutting site (Fig. 3a). Of the 10 3PN embryos that were injected, 7 showed editing and one of them resulted from HDR (Fig. 3b). Thus, at this locus, the HDR efficiency was 10%, which is lower than the 20% observed for injection with *G6PD* sgRNA1 and ssODN1. This result demonstrates that genetic modifications can be successfully introduced via HDR some distance away from the DSB in human embryos, but with decreased HDR efficiencies (Ran et al. 2013). However, sequencing of the targeted region showed the presence of both NHEJ repair

(within the *HBB* sgRNA1 sequence) and HDR on the same chromosome (Fig. 3c), indicating that re-editing occurred after HDR. In addition, this embryo also contained another independent edited allele (Fig. 3c). Thus, sgRNAs must be designed carefully to avoid the introduction of unintended alterations in the attempt to correct genetic defects.

### Correcting disease-causing mutations in human 2PN embryos

Having established that CRISPR/Cas9-mediated gene editing (NHEJ and HDR) could be achieved efficiently in human 3PN embryos, we decided to determine the editing efficiencies directly in human 2PN to assess the possibility of using CRISPR/Cas9 in correcting disease-causing mutations. To obtain human 2PN zygotes, wildtype immature oocytes were collected and subjected to in vitro maturation and ICSI procedures. We examined the disease-causing mutation β41–42 (-TCTT) in *HBB*. This is a common β-thalassemia mutation that results in a frameshift and generates a stop codon (TGA) at the position of the new 59th codon (Kimura et al. 1983). We collected sperm from a male patient who suffers from β-thalassemia and is heterozygous for the β41–42 mutation, as determined with a *HBB* genotyping kit. We designed an sgRNA (*HBB* sgRNA2) that specifically targets the mutant allele and a single-strand oligo donor (ssODN3) 90 nt in length as the template for HDR (Fig. 4a). We generated ten zygotes. Theoretically, half of the zygotes should be heterozygous for the corresponding mutation. However, at this stage it was not possible to determine which zygote carried the mutation. Thus, all fertilized embryos were injected with the Cas9/sgRNA/donor oligo mixture at the concentrations previously demonstrated to be safe for 3PN embryos. The injection was performed 18 h after ICSI. At this time point, the pronuclei were visible. The embryos were cultured for 2 days and then harvested for analyses. To assess the correction efficiency of the mutation in *HBB*, the genomic






**Fig. 3** Homologous recombination at *HBB*. **a** Diagram of the *HBB* locus, *HBB* sgRNA1 sequence (red), PAM motif (green), and the sequence of the single-strand donor oligo (ssODN2). The black arrows between nucleotides indicate the position of the Cas9 cut site

and the extra bases introduced at the site. **b** Analyses of the targeted *HBB* locus in ten embryos. M, DNA molecular weight marker, 1000, 750, 500, and 250 bp (top to bottom). \*T7E1 assay-positive samples, and \*\*HDR. **c** Sequencing results of embryo #3. (Color figure online)

region containing the mutation was amplified and subjected to T7E1 assay, HDR-diagnostic *Hind*III digestion, and sequencing. The expectation was that about half of the embryos would be heterozygous for the mutation and positive in the T7E1 assay. Indeed, four embryos were positive (#2, 4, 6, and 8) by the T7E1 assay but only one (#2) was digestible by *Hind*III (Fig. 4b). Sequencing analysis indicated that embryo #2 contained 3 *HBB* alleles: wildtype, corrected, and the (-TCTT, -C) mutant, at a ratio of 2:1:1 (Fig. 4c). Embryo #6 also contained three *HBB* alleles, but without HDR: wildtype, a -8 bp mutant, and a -174 bp mutant, at roughly 2:1:1 (Fig. 4c). Further sequencing of embryos #4 and #8 revealed that all the mutant alleles contained an additional C deletion within *HBB* sgRNA2 targeting site, which cannot be generated by DSB repair by the embryos. We then PCR amplified and sequenced the *HBB* sgRNA2 targeting site from the patient's genomic sample and confirmed that the *HBB* mutant allele genotype is (-TCTT, -C). Thus, the editing efficiency was 50% (two out of four embryos), slightly lower than that found for other loci (Table 1), and the HDR efficiency was 50% (one out of two edited embryos). These data indicated that the

CRISPR/Cas9 system may also tolerate a one base indel at the sgRNA targeting site in human zygotes using Cas9 protein (Lin et al. 2014b). The one base deletion in the *HBB*  $\beta$ 41-42 mutation *HBB* sgRNA2 targeting site could be an explanation of the observed lower targeting efficiency.

We next decided to test correction of the *G1376T* mutation at the X-linked *G6PD* locus in human 2PN zygotes, one of the two most common point mutations affecting the Chinese Han population (Du et al. 1999). First, we injected eight 3PN embryos to test the ability of the *G6PD* sgRNA3 to target the wildtype allele. None of the embryos was positive for T7E1 digestion, suggesting that the *G6PD* sgRNA3 specifically targeted the *G1376T* mutant allele. Next, we generated ten human 2PN zygotes using wildtype oocytes and sperm carrying the *G6PD* *G1376T* mutation. After injection, culturing, and testing, only two embryos were positive for T7E1 and *Hind*III digestion (Fig. 4e). Sequencing of the region indicated that embryo #2 contained one wildtype and one corrected *G6PD* allele at a roughly 1:1 ratio, and embryo #7 contained three different alleles, wildtype, corrected, and edited, at a ratio of 2:1:1 (Fig. 4f).



**Fig. 4** CRISPR/Cas9-mediated genome editing in one-cell human 2PN zygotes. **a** Diagram of the *HBB* locus, *HBB* sgRNA2 sequence (red), PAM motif (green), and the sequence of the single-strand donor oligo (ssODN3, silent mutations are in brown color). **b** Analyses of the targeted *HBB* β41–42 (-TCTT) mutant locus in ten embryos. M, DNA molecular weight marker, 1000, 750, 500, and 250 bp (top to bottom). \*T7E1 assay-positive samples, and \*\*HDR. **c** Sequencing results of T7E1 assay-positive embryo samples. These data

indicate that the *HBB* mutant type is β (-TCTT,-C). **d** Diagram of *G6PD* locus, *G6PD* sgRNA3 sequence (red), PAM motif (green), and the sequence of the single-strand donor oligo (ssODN4, silent mutations are in blue color). **e** Analyses of targeted *G6PD* G1376T mutant locus. M, DNA molecular weight marker, 1000, 750, 500, and 250 bp (top to bottom). \*T7E1 assay-positive samples, and \*\*HDR. **f** Sequencing results of embryos #2 and #7. **g** PCR detection of *SRY*. \*\*\*The absence of *SRY*. (Color figure online)

Further determination of the sex of the ten embryos showed that all embryos but #2 and #7 contained a Y chromosome (Fig. 4g). Thus, only these two embryos were XX, receiving one X chromosome from the sperm that contained the *G1376T* mutation. Thus, the sequencing of embryos #2 and #7 indicated HDR occurred, so the HDR efficiency was 100% (two out of two edited embryos). We further analyzed off-targeting in embryo #2. None of the 13 potential off-target sites identified with the CRISPR design tool (<http://tools.genome-engineering.org>) showed off-target effect. Sequencing data of the T7E1 assay-positive samples revealed no editing but polymorphisms at these sites (Fig. S1). Next, we sequenced the whole genome of embryo #2 to x30 coverage via next-generation sequencing. There were no large-scale alterations such as translocations and deletions. By allowing for ungapped alignments with up to four mismatches in the 20 bp *G6PD* sgRNA3 target sequence, and by scanning locus sequences that included 40 nt upstream and downstream of the on- and off-target

**Table 2** Whole genome sequencing analysis of embryo #2 in Fig. 4e

	Candidate off-target sites	SNP	InDel
sgRNA	CCTCAGCGACGAGCTCCT TG AGG		
Chr1	TCTCAGCGACCCGCTCCT TG AAA	rs435080	
Chr2	CCTCAGAGCCAAGCTCCTTG CAC		rs5833781
Chr2	CCTCAGAGAAGAGCTCATTG CAA	rs77248969	
Chr6	CCACAGCAGCGAGCTCCTTG AAA	rs9392482	
Chr7	ACTCAGCGACCAGCTCCTAG TGT	rs7806456	
Chr9	CCTCAGCCACTAGTACTTTG CCA	rs4879518 rs2502170	
Chr12	GCCCCGGCGACGAGCTCGTTG AGG	rs11062218 rs12578775 rs11062219	

site (a total of 100 bp), we obtained seven candidate off-target sites. However, these are all known SNPs and InDels (Table 2).

## Discussion

We demonstrate here that the CRISPR/Cas9 system is quite effective in correcting point mutations in human zygotes. For *G6PD*, only two mutation-carrying embryos were created and both underwent HDR on the mutant allele, so HDR occurred at 100%. One embryo was completely corrected and another became mosaic, with half of its cells corrected and another half suffered a 4-bp deletion around the mutation (Fig. 4f). For *HBB*, HDR occurred at 50% (one out of two edited embryos) (Fig. 4c; Table 1). However, HDR efficiency was much lower in 3PN embryos (20% for the *G6PD* sgRNA1-ssODN1 pair and 10% for the *HBB* sgRNA1-ssODN2 pair) (Fig. 2; Table 1). The explanation for these differences is currently unclear, but experimental data from a higher numbers of embryos are required to be meaningful.

Through whole genome sequencing, we did not find clear evidence of off-targeting in one of the two embryos with the G1376T-mutation corrected. However, the use of CRISPR/Cas9-mediated gene editing in reproductive clinics is not a current option due to both ethical and technical issues (safety, mosaicism, and other factors).

A potential application of CRISPR/Cas9 system in human zygotes is to study gene function in preimplantation development, an area of research with very limited numbers of molecular tools for humans, unlike the situation in other species. For example, one could introduce inactivating mutations and even point mutations to probe gene function in early human embryos.

**Acknowledgements** We thank Dr. Yuanfeng Li of Beijing Proteome Research Center and Dr. Zhongsheng Sun of Beijing Institutes of Life Science, Chinese Academy of Sciences for help with genome sequencing and analysis. We thank Dr. Xingxu Huang of the School of Life Science and Technology, Shanghai Tech University for helpful advice.

## Compliance with ethical standards

**Funding** This study was funded by a Grant from the Beijing Municipal Committee on Science and Technology (#Z141100000214015), by an international collaboration Grant from the Chinese Minister of Science and Technology (#2013DFB30210), by The National Basic Research Program (973 Program, No. 2013CB910300), by a Grant from the Science and Technology Program of Guangzhou, China (#2014KZDXM047), by The Innovation of Science and Technology Commission of Guangzhou, China (No. 201604020075), by The Department of Science and Technology of Guangdong, China (No. 2016A020218012), and a Grant from the China Postdoctoral Science Foundation (#2013M532214).

**Conflict of interest** All authors declare that they have no conflict of interest.

**Ethical approval** This study was approved by the ethics committee of the Third Affiliated Hospital of Guangzhou Medical University, numbered [2015] No. 068. The methods used in the present study closely followed the guidelines legislated and posted by the Ministry of Health of the People's Republic of China. The patients involved in this study knew about and understood the usage of trippronuclear zygotes, immature oocytes and leftover sperm, and voluntarily donated them after providing informed consent.

**Informed consent** Informed consent was obtained from all individual participants included in the study.

## References

- Capmany G, Taylor A, Braude PR, Bolton VN (1996) The timing of pronuclear formation, DNA synthesis and cleavage in the human 1-cell embryo. *Mol Hum Reprod* 2:299–306
- Chapman JR, Taylor MR, Boulton SJ (2012) Playing the end game: DNA double-strand break repair pathway choice. *Mol Cell* 47:497–510
- Chen F, Pruett-Miller SM, Huang Y, Gjoka M, Duda K, Taunton J, Collingwood TN, Frodin M, Davis GD (2011) High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. *Nat Methods* 8:753–755
- Chen S, Lee B, Lee AY, Modzelewski AJ, He L (2016) Highly efficient mouse genome editing by CRISPR ribonucleoprotein electroporation of zygotes. *J Biol Chem* 291:14457–14467
- Cho SW, Lee J, Carroll D, Kim JS, Lee J (2013) Heritable gene knockout in *Caenorhabditis elegans* by direct injection of Cas9-sgRNA ribonucleoproteins. *Genetics* 195:1177–1180
- Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. *Science* 339:819–823
- Du CS, Ren X, Chen L, Jiang W, He Y, Yang M (1999) Detection of the most common G6PD gene mutations in Chinese using amplification refractory mutation system. *Hum Hered* 49:133–138
- Hashimoto M, Yamashita Y, Takemoto T (2016) Electroporation of Cas9 protein/sgrRNA into early pronuclear zygotes generates non-mosaic mutants in the mouse. *Dev Biol* 418:1–9
- Hasty P, Rivera-Perez J, Bradley A (1991) The length of homology required for gene targeting in embryonic stem cells. *Mol Cell Biol* 11:5586–5591
- Heyer WD, Ehmsen KT, Liu J (2010) Regulation of homologous recombination in eukaryotes. *Annu Rev Genet* 44:113–139
- Kang X, He W, Huang Y, Yu Q, Chen Y, Gao X, Sun X, Fan Y (2016) Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing. *J Assist Reprod Genet* 33:581–588
- Kim S, Kim D, Cho SW, Kim J, Kim JS (2014) Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. *Genome Res* 24:1012–1019
- Kimura A, Matsunaga E, Takihara Y, Nakamura T, Takagi Y, Lin S, Lee H (1983) Structural analysis of a beta-thalassemia gene found in Taiwan. *J Biol Chem* 258:2748–2749
- Lee JS, Kwak SJ, Kim J, Kim AK, Noh HM, Kim JS, Yu K (2014) RNA-guided genome editing in *Drosophila* with the purified Cas9 protein. *G3 (Bethesda)* 4:1291–1295



- Li W, Teng F, Li T, Zhou Q (2013) Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. *Nat Biotechnol* 31:684–686
- Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y, Sun Y, Bai Y, Songyang Z, Ma W, Zhou C, Huang J (2015) CRISPR/Cas9-mediated gene editing in human triplo-nuclear zygotes. *Protein Cell* 6:363–372
- Lieber MR (2010) The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. *Annu Rev Biochem* 79:181–211
- Lin S, Staahl BT, Alla RK, Doudna JA (2014a) Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. *Elife* 3:e04766
- Lin Y, Cradick TJ, Brown MT, Deshmukh H, Ranjan P, Sarode N, Wile BM, Vertino PM, Stewart FJ, Bao G (2014b) CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. *Nucleic Acids Res* 42:7473–7485
- Ma Y, Shen B, Zhang X, Lu Y, Chen W, Ma J, Huang X, Zhang L (2014) Heritable multiplex genetic engineering in rats using CRISPR/Cas9. *PLoS One* 9:e89413
- Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA-guided human genome engineering via Cas9. *Science* 339:823–826
- Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, Kang Y, Zhao X, Si W, Li W, Xiang AP, Zhou J, Guo X, Bi Y, Si C, Hu B, Dong G, Wang H, Zhou Z, Li T, Tan T, Pu X, Wang F, Ji S, Zhou Q, Huang X, Ji W, Sha J (2014) Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. *Cell* 156:836–843
- Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y, Zhang F (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. *Cell* 154:1380–1389
- Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, Zhang X, Zhang P, Huang X (2013) Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. *Cell Res* 23:720–723
- Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* 153:910–918
- Zhou J, Shen B, Zhang W, Wang J, Yang J, Chen L, Zhang N, Zhu K, Xu J, Hu B, Leng Q, Huang X (2014) One-step generation of different immunodeficient mice with multiple gene modifications by CRISPR/Cas9 mediated genome engineering. *Int J Biochem Cell Biol* 46:49–55